Rifamycins--obstacles and opportunities.

@article{Aristoff2010RifamycinsobstaclesAO,
  title={Rifamycins--obstacles and opportunities.},
  author={Paul A Aristoff and George A. Garcia and Paul D. Kirchhoff and H. D. Hollis Showalter},
  journal={Tuberculosis},
  year={2010},
  volume={90 2},
  pages={94-118}
}
With nearly one-third of the global population infected by Mycobacterium tuberculosis, TB remains a major cause of death (1.7 million in 2006). TB is particularly severe in parts of Asia and Africa where it is often present in AIDS patients. Difficulties in treatment are exacerbated by the 6-9 month treatment times and numerous side effects. There is significant concern about the multi-drug-resistant (MDR) strains of TB (0.5 million MDR-TB cases worldwide in 2006). The rifamycins, long… CONTINUE READING
37 Citations
271 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 271 references

Mechanism of drug resistance in Mycobacterium tuber- culosis

  • MM Wade, Y. Zhang
  • Front Biosci 2004;9:975e94. P.A. Aristoff et al…
  • 2010

Development of new antituberculosis drugs: its relevance world- wide and in the Asia-Pacific region

  • Tam C-M
  • Respirology
  • 2008

Similar Papers

Loading similar papers…